IOL Chemicals & Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jqlmstulja7qbczqo2l9l9lb.pdf

Key Takeaways


Profitability: The Quality of the Beat

Mahajan: "The more EBITDA is primarily due to the internal efficiencies of the company, not primarily through the external factors."

Non-Ibuprofen: The Diversification Engine

Singh: "While ibuprofen remains an important part of our portfolio, our strategic focus is increasingly on building IOL as a diversified and integrated API platform, with multiple products contributing to our growth."

Chemical Segment: Quiet Strength


Paracetamol & New Products


Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growth15–20% growthFY27
FY27 EBITDA margin14–15%FY27
FY27 export contribution25–30% of revenueFY27
Paracetamol utilizationReach ~70% of enhanced capacityEnd of FY27
Non-ibuprofen pharma contributionReach ~50% of pharmaNear term
FY28 revenue growth15–20% top-line growthFY28, caveated on scenario holding
FY28 EBITDA margin15–17%FY28, caveated on scenario holding
FY29 non-ibuprofen API contribution50–55% of API segmentFY29
Triacetin regulatory approvalsApprovals expectedTwo to three quarters
Annual capex~₹200 Cr per year, 60% expansion/new products, 40% infrastructureOngoing, long-term view

What Management Would Not Say

Singh: "We need to be correct when we say something rather than we don't want to caught saying something which is not able to achieve."

Key Metrics

MetricQ1 FY27
Revenue from operations₹756 cr, up 37% YoY from ₹551 cr
EBITDA₹111 cr, up 60.7% YoY from ₹69.5 cr
EBITDA margin14.6%, up from 12.4% in Q1 FY26
PAT₹64.5 cr, up 89.9% YoY from ₹34 cr
PAT margin8.4%, up from 6.1% in Q1 FY26
Export contribution28.5% of revenue, up from 24.4% in Q1 FY26
Non-ibuprofen share of pharma revenue43%, up from 36% in Q1 FY26
Non-ibuprofen revenue growth67% YoY
Pharma revenue growth43% YoY
Paracetamol capacity utilization~55% of enhanced 10,800 MTPA capacity, expected to reach ~70% by end of FY27
Other pharma asset utilization80% to 95% capacity utilization
FY27 revenue growth guidance15% to 20%
FY27 EBITDA margin guidance14% to 15%
FY27 export guidance25% to 30% of revenue
FY28 revenue growth guidance15% to 20%
FY28 EBITDA margin guidance15% to 17%
FY29 non-ibuprofen target50% to 55% of API segment
Capex guidance₹200 cr to ₹250 cr, 60% for expansion and new products, 40% for infrastructure
R&D investment in FY26₹26 cr
Triacetin revenue potential~₹120 cr per year at steady state
US FDA approved products5 products approved, another 2 to 3 in pipeline via formulators' ANDA filings